Physician profile
Thomas Kendall
NPI 1407905334
$1,506.92
in general payments reported to CMS, 2019-2025
22 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $221 · 2021: $459 · 2022: $257 · 2023: $126 · 2024: $195 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $344.35 | 2020-2023 | Xarelto |
| Abbvie INC. | $253.61 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $170.95 | 2019-2023 | |
| Daiichi Sankyo INC. | $115.56 | 2019-2024 | Injectafer |
| Novo Nordisk INC | $96.22 | 2019-2024 | Rybelsus |
| Exact Sciences Corporation | $75.78 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $59.76 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $48.89 | 2019-2021 | |
| Pfizer INC. | $38.21 | 2019-2020 | |
| Lilly USA, LLC | $36.19 | 2021-2024 | Mounjaro |
| Astellas Pharma US INC | $34.28 | 2021 | |
| Abbott Laboratories | $33.26 | 2024 | Proclaim |
| Phathom Pharmaceuticals, INC. | $31.89 | 2025 | Voquezna |
| Dexcom, INC. | $26.09 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $23.95 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $23.67 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $18.44 | 2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Quidel Corporation | $16.33 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.05 | 2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $15.95 | 2023 | Breztri |
| Allergan, INC. | $14.43 | 2020 | |
| Esperion Therapeutics, INC. | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kendall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.